Tweet
J Med Virol
. 2024 Aug;96(8):e29812.
doi: 10.1002/jmv.29812. Fecal microbiota transplantation alleviates mild-moderate COVID-19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double-blind clinical trial
Xia Jiang 1 2 , Xian Gao 1 2 , Jiaqi Ding 1 2 , Bo Pang 1 2 , Yongbin Pei 3 , Zifeng Zhao 2 , Ning Zhao 2 , Zibin Wang 2 , Chengyang Chen 2 , Da Gao 2 , Fu Yan 2 , Feifan Wang 2 , Chengcheng Liu 2 , Zheng Zhang 4 , Zhongxin Li 1 2 , Zengren Zhao 1 2
Affiliations
Currently, the emergence of the endemic Coronavirus disease (COVID-19) situation still poses a serious threat to public health. However, it remains elusive about the role of fecal microbiota transplantation in treating COVID-19. We performed a randomized, double-blind, placebo-controlled clinical trial enrolling a cohort of 40 COVID-19 patients with mild-moderate symptoms. Our results showed that fecal microbiota transplantation provided an amelioration in diarrhoea (p = 0.026) of digestive system and depression (p = 0.006) of neuropsychiatric-related symptom in COVID-19 patients, respectively. Meanwhile, we found that the number of patients with diarrhoea decreased from 19 to 0 on day 7 after fecal microbiota transplantation treatment, and it was statistically changed compared to the placebo group (p = 0.047). Of note, the serum concentration of aspartate aminotransferase-to-alanine aminotransferase ratio (AST/ALT, fecal microbiota transplantation, pre vs. post: 0.966 vs. 0.817), a biomarker for predicting long COVID-19, was significantly reduced by fecal microbiota transplantation. In all, our study supports that fecal microbiota transplantation could be a novel therapeutic strategy for COVID-19 patients with diarrhoea and depressive symptoms, which is potentially valuable in ameliorating long COVID-19 symptoms.
Keywords: AST/ALT; COVID‐19; SARS‐CoV‐2; depression; diarrhoea; fecal microbiota transplantation.
. 2024 Aug;96(8):e29812.
doi: 10.1002/jmv.29812. Fecal microbiota transplantation alleviates mild-moderate COVID-19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double-blind clinical trial
Xia Jiang 1 2 , Xian Gao 1 2 , Jiaqi Ding 1 2 , Bo Pang 1 2 , Yongbin Pei 3 , Zifeng Zhao 2 , Ning Zhao 2 , Zibin Wang 2 , Chengyang Chen 2 , Da Gao 2 , Fu Yan 2 , Feifan Wang 2 , Chengcheng Liu 2 , Zheng Zhang 4 , Zhongxin Li 1 2 , Zengren Zhao 1 2
Affiliations
- PMID: 39056206
- DOI: 10.1002/jmv.29812
Currently, the emergence of the endemic Coronavirus disease (COVID-19) situation still poses a serious threat to public health. However, it remains elusive about the role of fecal microbiota transplantation in treating COVID-19. We performed a randomized, double-blind, placebo-controlled clinical trial enrolling a cohort of 40 COVID-19 patients with mild-moderate symptoms. Our results showed that fecal microbiota transplantation provided an amelioration in diarrhoea (p = 0.026) of digestive system and depression (p = 0.006) of neuropsychiatric-related symptom in COVID-19 patients, respectively. Meanwhile, we found that the number of patients with diarrhoea decreased from 19 to 0 on day 7 after fecal microbiota transplantation treatment, and it was statistically changed compared to the placebo group (p = 0.047). Of note, the serum concentration of aspartate aminotransferase-to-alanine aminotransferase ratio (AST/ALT, fecal microbiota transplantation, pre vs. post: 0.966 vs. 0.817), a biomarker for predicting long COVID-19, was significantly reduced by fecal microbiota transplantation. In all, our study supports that fecal microbiota transplantation could be a novel therapeutic strategy for COVID-19 patients with diarrhoea and depressive symptoms, which is potentially valuable in ameliorating long COVID-19 symptoms.
Keywords: AST/ALT; COVID‐19; SARS‐CoV‐2; depression; diarrhoea; fecal microbiota transplantation.